NZ312502A - Clostridium difficile toxins as mucosal adjuvants - Google Patents
Clostridium difficile toxins as mucosal adjuvantsInfo
- Publication number
- NZ312502A NZ312502A NZ312502A NZ31250296A NZ312502A NZ 312502 A NZ312502 A NZ 312502A NZ 312502 A NZ312502 A NZ 312502A NZ 31250296 A NZ31250296 A NZ 31250296A NZ 312502 A NZ312502 A NZ 312502A
- Authority
- NZ
- New Zealand
- Prior art keywords
- clostridium difficile
- mucosal adjuvants
- difficile toxins
- mammal
- antigen
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 239000003053 toxin Substances 0.000 title abstract 2
- 231100000765 toxin Toxicity 0.000 title abstract 2
- 108700012359 toxins Proteins 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 241000193403 Clostridium Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49938495A | 1995-07-07 | 1995-07-07 | |
| US08/543,708 US5919463A (en) | 1995-07-07 | 1995-10-16 | Clostridium difficle toxins as mucosal adjuvants |
| PCT/US1996/011142 WO1997002836A1 (en) | 1995-07-07 | 1996-07-01 | Clostridium difficile toxins as mucosal adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ312502A true NZ312502A (en) | 1999-03-29 |
Family
ID=27053134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ312502A NZ312502A (en) | 1995-07-07 | 1996-07-01 | Clostridium difficile toxins as mucosal adjuvants |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0837692B1 (enExample) |
| JP (1) | JPH11509200A (enExample) |
| CN (1) | CN1195297A (enExample) |
| AT (1) | ATE195878T1 (enExample) |
| AU (1) | AU720567B2 (enExample) |
| CA (1) | CA2226339A1 (enExample) |
| DE (1) | DE69610106D1 (enExample) |
| NZ (1) | NZ312502A (enExample) |
| WO (1) | WO1997002836A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9626864D0 (en) * | 1996-12-24 | 1997-02-12 | Smithkline Beecham Biolog | Vaccine |
| AU746859B2 (en) * | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6214341B1 (en) | 1997-10-20 | 2001-04-10 | Oravax | Passive immunization against Clostridium difficile disease |
| EP1568378B1 (en) * | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
| AU6524798A (en) * | 1998-03-31 | 1999-10-18 | Dae Woong Pharmaceutical Co., Ltd. | A preventive and therapeutic vaccine for (helicobacter pylori)-associated diseases |
| EP1165796A2 (en) * | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| US6733760B1 (en) | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| WO2000061762A1 (en) * | 1999-04-09 | 2000-10-19 | Techlab, Inc. | RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE) |
| AU2011238711B2 (en) | 2010-03-30 | 2015-06-18 | Pelican Technology Holdings, Inc. | High level expression of recombinant toxin proteins |
| CN103957931B (zh) | 2010-09-03 | 2017-10-24 | 瓦尔内瓦奥地利有限责任公司 | 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途 |
| SI3505531T1 (sl) | 2011-04-22 | 2024-02-29 | Wyeth Llc | Kompozicije, povezane z mutantnim toksinom clostridium difficile in njegovimii metodami |
| CN103732750A (zh) * | 2011-05-27 | 2014-04-16 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| MX2014006630A (es) | 2011-12-08 | 2014-07-09 | Novartis Ag | Vacuna a base toxina clostridium difficile. |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4944942A (en) * | 1987-08-27 | 1990-07-31 | Mobay Corporation | Intranasal vaccination of horses with inactivated microorganisms or antigenic material |
| JP2849632B2 (ja) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| IL106362A (en) * | 1992-07-16 | 1998-12-06 | Oxford University | A system for launching multiple particle antigens |
| GB9305919D0 (en) * | 1993-03-22 | 1993-05-12 | Health Lab Service Board | Botulinum toxin polypeptides and their use as vaccines |
-
1996
- 1996-07-01 JP JP9505861A patent/JPH11509200A/ja active Pending
- 1996-07-01 AU AU64047/96A patent/AU720567B2/en not_active Ceased
- 1996-07-01 NZ NZ312502A patent/NZ312502A/xx unknown
- 1996-07-01 CN CN96196777A patent/CN1195297A/zh active Pending
- 1996-07-01 CA CA002226339A patent/CA2226339A1/en not_active Abandoned
- 1996-07-01 AT AT96923569T patent/ATE195878T1/de active
- 1996-07-01 DE DE69610106T patent/DE69610106D1/de not_active Expired - Lifetime
- 1996-07-01 WO PCT/US1996/011142 patent/WO1997002836A1/en not_active Ceased
- 1996-07-01 EP EP96923569A patent/EP0837692B1/en not_active Revoked
Also Published As
| Publication number | Publication date |
|---|---|
| DE69610106D1 (de) | 2000-10-05 |
| CA2226339A1 (en) | 1997-01-30 |
| AU6404796A (en) | 1997-02-10 |
| EP0837692A4 (enExample) | 1998-04-29 |
| AU720567B2 (en) | 2000-06-08 |
| CN1195297A (zh) | 1998-10-07 |
| EP0837692A1 (en) | 1998-04-29 |
| JPH11509200A (ja) | 1999-08-17 |
| EP0837692B1 (en) | 2000-08-30 |
| ATE195878T1 (de) | 2000-09-15 |
| WO1997002836A1 (en) | 1997-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ312502A (en) | Clostridium difficile toxins as mucosal adjuvants | |
| ATE326231T1 (de) | Mutierendes enterotoxin als nichttoxisches orales adjuvans | |
| ATE127345T1 (de) | Stressproteine und verwendungen dafür. | |
| ATE211654T1 (de) | Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff | |
| EP1170016A3 (en) | Urease-based vaccine against helicobacter infection | |
| TR199801722T2 (xx) | Peptit imm�nojenler. | |
| ATE188508T1 (de) | Impfstoffe gegen diphtherietoxin | |
| AU1934088A (en) | Saponin adjuvant | |
| AP2000001886A0 (en) | Group B streptococcus antigens. | |
| EP1385541A4 (en) | IMMUNOSTIMULATING COMBINATIONS CONTAINING AMINO ALKYL GLUCOSAMINE IDEPHOSPHATE AND QS-21 | |
| GB9808327D0 (en) | Antidiotypic compounds | |
| AUPM885194A0 (en) | Synthetic peptides and vaccines comprising same | |
| AU2917697A (en) | Dendritic cell receptor | |
| WO1994010317A3 (en) | Conjugate vaccine against group b streptococcus | |
| HUP9801223A2 (hu) | Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel | |
| ES483374A1 (es) | Procedimiento para modificar las propiedades antigenas de unantigeno de polen de la hierba | |
| KR100218138B1 (en) | Methods and vaccines comprising surface-active copolymers | |
| WO1999065518A3 (en) | Lt and ct in parenteral immunization methods against helicobacter infection | |
| AU4545096A (en) | Polypeptide fragments capable of competition with streptococcus mutans antigen i/ii | |
| DK0725653T3 (da) | Vaccinepræparater | |
| ZA919907B (en) | Use of il-4 to enhance immune response to immunogens in vaccines | |
| ATE234109T1 (de) | Cetp zur erhöhung des hdl-cholesterol-gehalts | |
| SE9604322D0 (sv) | Bacterial antigens and vaccine compositions II | |
| WO2002004497A3 (en) | Multiple antigenic peptides immunogenic against streptococcus pneumoniae | |
| NZ333191A (en) | Human dendritic cell receptor DEC-205 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |